Disclaimer: This guide is educational content only and does not constitute medical advice. CJC-1295 is not FDA-approved for human use. Consult a qualified healthcare provider before use, especially if you have active malignancies, diabetic retinopathy, or significant insulin resistance.
CJC-1295 (Modified GRF 1-29) is a synthetic peptide that stimulates growth hormone release in the body. Unlike natural growth hormone-releasing hormone, which has a half-life measured in minutes, CJC-1295 uses Drug Affinity Complex (DAC) technology to extend its active duration to 6-8 days per injection. This extended half-life allows for once-weekly dosing rather than daily administration.
The peptide works by binding to GHRH receptors on pituitary somatotroph cells, triggering pulsatile growth hormone secretion. Elevated GH subsequently increases IGF-1 production in the liver, which mediates downstream effects on muscle, fat, and tissue recovery. CJC-1295 is commonly used alongside GHRP compounds (such as Ipamorelin) to amplify growth hormone release synergistically.
The established dosage range for CJC-1295 is 1,000–2,000 micrograms (1–2 mg) administered once per week via subcutaneous injection.
Weekly Protocol:
- Standard dose: 1,500 mcg (1.5 mg) once weekly
- Conservative dose: 1,000 mcg (1 mg) once weekly
- Higher dose: 2,000 mcg (2 mg) once weekly
- Injection frequency: 1 time per week (7-day intervals)
- Route: Subcutaneous injection only
- Best timing: Consistent day each week (e.g., Monday morning)
A single injection produces 2–10 fold increases in plasma growth hormone levels sustained for 6 or more days, with IGF-1 elevation lasting 9–11 days. Multiple weekly doses maintain IGF-1 levels above baseline for up to 28 days.
While CJC-1295 consistently elevates growth hormone and IGF-1, research demonstrating efficacy for specific outcomes (muscle gain, fat loss, injury recovery) remains limited in humans. The following represents practical dosing strategies based on user objectives and tolerability:
- Dose: 1,000–1,500 mcg weekly
- Rationale: Lower end establishes baseline GH elevation without excessive side effects. Sufficient to maintain 2–5 fold GH increases and 1.5–2 fold IGF-1 elevation throughout the week.
- Duration: 12–24 weeks minimum to assess hormonal response
- Dose: 1,500–2,000 mcg weekly
- Rationale: Higher doses may support greater IGF-1 signaling, though human evidence for muscle gain is absent. Often paired with Ipamorelin (200–300 mcg twice daily) for synergistic effects.
- Duration: 16–24 weeks
- Note: No human studies directly measure muscle growth from CJC-1295 dosing
- Dose: 500–1,000 mcg weekly (lower than standard)
- Rationale: Starting dose for users sensitive to side effects or assessing individual response. Some users report adequate GH elevation at 1,000 mcg.
- Duration: 4–8 weeks, then reassess
- Route: Subcutaneous injection only (abdomen, thigh, or upper arm)
- Needle: 29–31 gauge, 0.5–1 inch length
- Volume: CJC-1295 is dosed in micrograms, typically reconstituted as 1–2 mg per vial. Injection volume is typically 0.1–0.2 mL per dose.
- Draw bacteriostatic water into syringe (amount varies by vial concentration)
- Inject water slowly into vial containing CJC-1295 powder
- Allow 5–10 minutes for complete dissolution (do not shake vigorously)
- Solution should be clear; discard if discolored or cloudy
- Store in refrigerator (2–8°C); do not freeze
- Use within 30 days of reconstitution if using bacteriostatic water
- Clean injection site with alcohol swab
- Pinch skin to create subcutaneous space
- Insert needle at 45–90 degree angle
- Inject slowly over 3–5 seconds
- Remove needle and apply light pressure with clean gauze
- Rotate injection sites to minimize irritation
- Inject at the same time each week for consistency
- Morning injection is common, though timing relative to food is not critical
- Some users report reduced water retention and flushing if injected in the evening
- No specific pre- or post-injection meal requirements
- On-cycle: 12–24 weeks of once-weekly CJC-1295 dosing
- Off-cycle: 4–8 weeks without CJC-1295 before restarting
- Rationale: Extended off-periods allow pituitary GHRH receptor sensitivity to recover and limit long-term unknown risks
- Weeks 1–16: 1,500 mcg CJC-1295 every 7 days
- Weeks 17–20: Off (no injection)
- Weeks 21–36: Optional second cycle
- Continuous (12–24 weeks on, 4–8 weeks off): Most common approach; balances convenience with periodic recovery
- Pulsed (2 weeks on, 1 week off): Alternative strategy to reduce side effects and maintain receptor sensitivity; requires more cycles to reach steady-state IGF-1
- Year-round: Not recommended without medical supervision, given limited long-term safety data
CJC-1295 is frequently combined with:
- Ipamorelin: 200–300 mcg twice daily (amplifies GH release; synergistic with CJC-1295)
- GHRP-6 or GHRP-2: 100–200 mcg 2–3 times daily (alternative GHRP option)
When stacking, maintain the same CJC-1295 weekly dose; adjust the GHRP dosing based on tolerability.
- Week 1–4: 1,000 mcg CJC-1295 once weekly (assess tolerance)
- Week 5–12: Increase to 1,500 mcg weekly if no adverse effects
- Typical stack: CJC-1295 alone (no GHRP stacking initially)
- Assessment: Monitor injection site reactions, water retention, appetite changes, and energy levels
- Cost expectation: $40–$120 per month for CJC-1295 alone
- Dose: 1,500–2,000 mcg CJC-1295 weekly
- Stack: CJC-1295 + Ipamorelin (200–300 mcg twice daily)
- Cycling: 16–20 week on-cycle, 6–8 week off-cycle
- Timing: Precise injection timing and rotation between sites
- Monitoring: Blood work to assess IGF-1 and GH levels; some users obtain baseline and mid-cycle labs
- Cost expectation: $80–$240+ per month (including GHRP)
Dosing above 2,000 mcg per week increases side effect risk (water retention, flushing, joint pain) without proportional benefit. The standard 1,000–2,000 mcg range covers the effective dose-response curve.
CJC-1295's long half-life (5.8–8.1 days) makes twice-weekly dosing unnecessary and wasteful. Stick to once-weekly injection; IGF-1 remains elevated for days.
Inconsistent weekly timing disrupts steady-state GH and IGF-1 levels. Select one day per week (e.g., Monday) and maintain it throughout the cycle.
Repeatedly injecting the same site leads to lipohypertrophy (fat pad enlargement) and increased local irritation. Rotate between abdomen, thighs, and upper arms.
Improperly stored reconstituted CJC-1295 (exposed to heat, light, or freezing) degrades peptide integrity. Keep refrigerated at 2–8°C and use within 30 days.
Combining CJC-1295 with other growth hormone secretagogues at full doses (e.g., CJC-1295 + GHRP-6 at maximum doses simultaneously) may cause excessive GH spikes and exaggerated side effects. Stagger doses or reduce individual doses when stacking.
Running CJC-1295 continuously for years without breaks is not validated by safety data. Standard practice includes 4–8 week off-periods every 12–24 weeks.
| Parameter | Details |
|---|
| Standard Dose | 1,000–2,000 mcg (1–2 mg) |
| Typical Dose | 1,500 mcg (1.5 mg) |
| Frequency | Once weekly (every 7 days) |
| Route | Subcutaneous injection |
| Half-life | 5.8–8.1 days |
| GH Peak | 2–10 fold increase, sustained 6+ days |
| IGF-1 Duration | 9–11 days elevation; 28+ days with repeated dosing |
| On-Cycle Duration | 12–24 weeks |
| Off-Cycle Duration | 4–8 weeks |
| Beginner Dose | 1,000 mcg weekly |
| Advanced Dose | 1,500–2,000 mcg weekly (often with GHRP stack) |
| Cost | $40–$120 per month (CJC-1295 alone) |
| Injection Sites | Abdomen, thighs, upper arms (rotate) |
| Storage | Refrigerated (2–8°C); use within 30 days of reconstitution |
CJC-1295 dosing is straightforward: inject 1,000–2,000 mcg subcutaneously once weekly. The extended half-life eliminates the need for daily administration and allows flexibility in timing, though consistency is important for steady hormone levels.
Beginners should start at 1,000 mcg weekly to assess tolerability before advancing to higher doses. Advanced users often pair CJC-1295 with a GHRP (Ipamorelin, GHRP-6, or GHRP-2) to maximize GH release, though this increases complexity and cost.
Most users cycle 12–24 weeks on, followed by 4–8 weeks off, to balance hormone elevation with long-term safety considerations. Practical administration requires subcutaneous injection technique, proper reconstitution and storage, and consistent weekly timing.
Common mistakes—exceeding 2,000 mcg, injecting too frequently, poor site rotation, and inadequate cycling—reduce efficacy and increase side effects. Avoid these pitfalls by adhering to the standard protocol outlined above.
While CJC-1295 reliably elevates growth hormone and IGF-1 in humans, direct evidence for muscle growth, fat loss, injury recovery, or other specific outcomes remains limited. Use this peptide with realistic expectations and awareness that you are participating in research-grade use outside FDA approval.